"In parallel with the preparations for the Phase III study, we are strengthening our presence and visibility in academia and the medical profession and intensifying the work for an upcoming ...

Current eosinophilic esophagitis treatment guidelines include dietary modifications, medications, and endoscopic procedures.

Edmund Pezalla, MD, MPH, spoke with Physician’s Weekly about findings that show proton pump inhibitors may not increase risk ...

The Proton eMas 7 continues to make its way to export markets, with the electric SUV having been previewed in Singapore at The Car Expo 2025 at Singapore Expo this past weekend. The national ...

A health expert has warned that taking certain tablets for an extended period of time could increase your risk of developing dementia.

The Proton eMas 7 will be shown at The Car Expo that takes place in Singapore this weekend, according to the Proton eMas Singapore Facebook page. According to the post, the eMas 7 will be offered ...

The court’s direction came on a petition filed by a Bengaluru-based firm, M Moser Design, seeking a direction to the Union ministry of electronics and information technology to ban Proton Mail ...

Key Laboratory of Photochemistry, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China University of Chinese ...

The Geely Xingyuan, a fully electric (EV) hatchback showcased at the Shanghai Auto Show 2025, is confirmed to be heading to Malaysia as the second Proton eMAS model. It would be called as the Proton ...

Other options include histamine-2 (H2) antagonists and proton pump inhibitors (PPIs), which take some time to work. These drugs help neutralize or reduce stomach acid. The latter drugs can also ...

1Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois. *Corresponding Author: Hilary A. Kenny, Department of Obstetrics and Gynecology, ...

"The initiation of this clinical trial marks an important milestone in advancing our novel WRN inhibitor program," said Anita Scheuber, M.D., Ph.D., Senior Vice President, Therapeutic Head, Oncology ...